

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions and listings of the claims in the application.

Listing of claims

What is claimed:

- 1-48. (cancelled)
49. (Previously Presented) A purified polypeptide the amino acid sequence of which comprises SEQ ID NO: 2, or a degenerate variant of SEQ ID NO: 2.
50. (Currently Amended) The purified polypeptide of claim ~~49~~ 46 where said variant is a fragment, said fragment comprising at least 5 consecutive amino acids, wherein said polypeptide is immunologically reactive with an anti-GBS phage lysin antibody.
51. (Currently Amended) The purified polypeptide of claim ~~49~~ 46 where said sequence comprises an amino acid sequence which is at least 80% identical to SEQ ID NO: 2.
52. (Currently Amended) The purified polypeptide of claim ~~49~~ 46 where said sequence comprises an amino acid sequence which is at least 60% identical to SEQ ID NO: 2.
53. (Currently Amended) The purified polypeptide of claim ~~49~~ 46 where said variant is a fragment, said fragment comprising an amino acid sequence selected from the group consisting of: residues 1-107, residues 6-107, residues 6-443, residues 1-344, residues 145-344, residues 145-443 and residues 6-344, where the polypeptide express at least one of an endopeptidase or a glycosidase activity.
54. (Currently Amended) The purified polypeptide of claim ~~49~~ 46 where said variant is a mutant, said mutant being characterized as having at least one of the following characteristics: (i) having a serine residue at position 26; (ii) having a serine residue at position 44; or (iii) having a serine residue at position 26 and position 44. ~~(a) at position 26 the amino acid cysteine is replaced by serine; (b) at position 44 the amino acid cysteine is replaced by serine; or (c) both (a) and (b).~~
55. (Currently Amended) The purified polypeptide of claim ~~54~~ 50 where said variant s does not express an endopeptidase activity.